Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety

被引：7
|
作者：
Trstenjak, Uros [1 ]
Ilas, Janez [1 ]
Kikelj, Danijel [1 ]
机构：
[1] Univ Ljubljana, Fac Pharm, Ljubljana 1000, Slovenia
来源：
MEDCHEMCOMM | 2014年 / 5卷 / 02期
关键词：
PLATELET-AGGREGATION; THROMBIN; DISCOVERY; POTENT; WEIGHT; DESIGN; SERIES;
D O I：
10.1039/c3md00250k
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Replacement of the P-4 morpholin-3-one moiety in a selective factor Xa inhibitor rivaroxaban by 2-ethoxycarbonylpiperidine resulted in a dual factor Xa/thrombin inhibitor 24, possessing a K-i of 62 +/- 18 nM for factor Xa and a K-i of 353 +/- 75 nM for thrombin. Presented rationalization of dual activity provides a good starting point for "designing in" thrombin inhibitory activity to potent factor Xa inhibitor rivaroxaban.
引用
收藏
页码：197 / 202
页数：6
相关论文
共 50 条
  • [41] Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa
    Graefe-Mody, E. U.
    Schuehly, U.
    Rathgen, K.
    Staehle, H.
    Leitner, J. M.
    Jilma, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (07) : 1502 - 1509
  • [42] Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry
    Xu, Zhe
    Liu, Ruonan
    Guan, Huashi
    ANALYTICA CHIMICA ACTA, 2017, 990 : 1 - 10
  • [43] Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits
    Wong, P. C.
    Crain, E. J.
    Watson, C. A.
    Xin, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (08) : 1313 - 1320
  • [44] The new factor Xa inhibitor: Apixaban
    Bhanwra, Sangeeta
    Ahluwalia, Kaza
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (01) : 12 - 14
  • [45] Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
    Graff, Jochen
    von Hentig, Nils
    Misselwitz, Frank
    Kubitza, Dagmar
    Becka, Michael
    Breddin, Hans-Klaus
    Harder, Sebastian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (11): : 1398 - 1407
  • [46] Effects of rivaroxaban, a novel, oral, direct Factor Xa inhibitor, on coagulation assays
    Samama, M. M.
    Fem, L. L.
    Guinet, C.
    Perzborn, E.
    Martinoli, J.
    Depasse, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 693 - 693
  • [47] Effects of rivaroxaban, a novel, oral, direct factor Xa inhibitor, on coagulation assays
    Samama, M. M.
    Le Flem, L.
    Guinet, C.
    Perzborn, E.
    Martinoli, J-L
    Depasse, F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 35 - 36
  • [48] EFFECT OF THE NOVEL, ORAL, DIRECT FACTOR XA INHIBITOR RIVAROXABAN ON COAGULATION ASSAYS
    Samama, M. M.
    Le Flem, L.
    Guinet, C.
    Perzborn, E.
    Marinoli, J. -L.
    Depasse, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 178 - 178
  • [49] Orally Administered Factor Xa Inhibitor, Rivaroxaban: A Novel Thromboembolic Prophylaxis Agent
    Komotar, Ricardo J.
    Starke, Robert M.
    Connolly, E. Sander, Jr.
    NEUROSURGERY, 2008, 63 (04) : N10 - N11
  • [50] Preclinical and clinical characteristics of rivaroxaban: A novel, oral, direct factor Xa inhibitor
    Laux, Volker
    Perzborn, Elisabeth
    Kubitza, Dagmar
    Misselwitz, Frank
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (05): : 515 - 523
12345